Yaacov Michlin- Chairman
Mr. Michlin is the President and Chief Executive Officer of Yissum, the technology transfer company of the Hebrew University of Jerusalem. Mr. Michlin has been leading and assisting pharmaceutical, Hi-tech and biomedical companies (including Teva, Bioline, CBI and Brainsway) in various technology commercialization deals, licensing agreements, capital raising, mergers and acquisitions and joint venture collaborations. Prior to joining Yissum, Mr. Michlin was a partner at Tulchinsky Stern & Co. Law Offices. He holds a Bachelor of Law and Economics, cum laude, and a Master of Law degree, both from Bar-Ilan University, Israel, and an MBA, cum laude, from the Technion Israel Institute of Technology, Israel.
Professor Marta Weinstock-Rosin
Professor Weinstock-Rosin, co-inventor of Ladostigil, is Professor Emeritus at the Hebrew University, Jerusalem, Israel. She was Chairperson of the Department of Pharmacology from 1983-1986, and President of the Israel Society for Neuroscience from 2003-2005. She was awarded the Kaye prize for the invention of Exelon in 2000 and was the first person working in a University to be awarded a prize by the Institute of Ageing, USA for inventing Rivastigmine (Exelon®, Novartis Pharmaceuticals), a drug for the treatment of Alzheimer’s Disease.
Professor Yigal Koltin
Professor Koltin served for more than 25 years as Professor of Genetics at Tel Aviv University, and has spent more than 20 years in various capacities in the pharmaceutical and biopharmaceutical industries. In 1992 he cofounded ChemGenics Pharmaceuticals which merged in 1997 with Millennium Pharmaceuticals where he served as Vice President of Program Management covering more than 10 disease indications. He served the board of directors of Tel Aviv University-Kellog School of Hi-Tech Management. He has served or is serving on the board of directors or scientific advisory board of numerous companies including Procognia, Xanthus Life Sciences, Remon Biomedical, Quantomix, RadBio Accelerator, and ActiveP (Israel).
Mr. Gonen is Vice President at Clal Biotechnology Industries Ltd (TASE: CBI), the largest biotechnology investment group in Israel. CBI targets promising companies with innovative bio-pharma technologies and transforms them into thriving and productive businesses. Mr. Gonen is responsible for business development for CBI’s portfolio companies and works closely with co-investors and strategic partners. A veteran of Talpiot, the prestigious IDF technology unit, Mr. Gonen gained extensive technology and R&D experience in his military service, during which he was awarded the Israeli National Security Medal. Mr. Gonen received his MA in Economics and Finance from the Tel Aviv University and a BSc in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem.
Mr. Kariv, a seasoned venture capital industry executive, is CEO of the Pontifax Funds, which he founded in 2005 together with Eli Hurvitz, former Chairman and CEO of Teva Pharmaceutical Industries. For the past 15 years, Mr. Kariv has played a key role in investing, managing and nurturing technology driven companies and startups. Mr. Kariv holds a BA in Economics from Harvard University and a Juris Doctor from Harvard Law School.